Chemours (NYSE:CC) Upgraded to "Outperform" at Mizuho

Mizuho upgraded shares of Chemours (NYSE:CC - Free Report) from a neutral rating to an outperform rating in a report published on Thursday morning, MarketBeat reports. They currently have $19.00 price objective on the specialty chemicals company's stock.

Several other research firms have also recently weighed in on CC. Barclays dropped their price objective on Chemours from $23.00 to $19.00 and set an "equal weight" rating for the company in a report on Monday, February 24th. The Goldman Sachs Group dropped their price target on Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. BMO Capital Markets reduced their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 19th. Truist Financial started coverage on shares of Chemours in a research report on Tuesday, January 28th. They issued a "buy" rating and a $27.00 target price for the company. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $25.00 target price on shares of Chemours in a research note on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $22.89.

Remove Ads

Chemours Trading Down 1.4 %

Shares of Chemours stock traded down $0.19 on Thursday, hitting $13.53. The stock had a trading volume of 552,359 shares, compared to its average volume of 1,723,448. The stock's 50-day simple moving average is $16.41 and its two-hundred day simple moving average is $18.21. Chemours has a one year low of $13.09 and a one year high of $29.21. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 23.69 and a beta of 2.00.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $1.36 billion for the quarter, compared to analysts' expectations of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, sell-side analysts predict that Chemours will post 2.03 EPS for the current year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 7.39%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's dividend payout ratio is 175.44%.

Institutional Trading of Chemours

Hedge funds have recently made changes to their positions in the stock. Quest Partners LLC raised its stake in Chemours by 7,206.4% during the third quarter. Quest Partners LLC now owns 7,964 shares of the specialty chemicals company's stock valued at $162,000 after buying an additional 7,855 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Chemours by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company's stock worth $24,974,000 after purchasing an additional 32,590 shares during the last quarter. Truvestments Capital LLC bought a new position in Chemours in the 3rd quarter worth about $35,000. FMR LLC grew its position in Chemours by 3.5% during the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company's stock valued at $368,650,000 after purchasing an additional 618,361 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new stake in Chemours during the 3rd quarter valued at about $37,000. 76.26% of the stock is owned by institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.